drugset / Trial / NCT02662894

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

NCT02662894

Phase 3 Withdrawn EMS
RandomizedParallel-groupOpen-labelTreatment

Summary

Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.

Timeline

Start
2019-10
Primary completion
2020-09
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Valsartan Small molecule 160 mg Oral
Subject Valsartan Small molecule 320 mg Oral